Literature DB >> 17275850

Increased amyloid beta protein levels in children and adolescents with Down syndrome.

Pankaj D Mehta1, George Capone, Amy Jewell, Robert L Freedland.   

Abstract

BACKGROUND: Persons with Down syndrome (DS) (40 years and older) have neuropathological changes characteristic of Alzheimer disease (AD). Soluble forms of amyloid beta (Abeta) peptide generated from amyloid precursor protein (APP) end at C-terminal residues 40 and 42. The presence of the apolipoprotein E (ApoE) epsilon4 allele is a significant risk factor for the development of sporadic AD. Although preliminary studies have shown an association of plasma Abeta42 and ApoE epsilon4 allele in older persons with DS who have dementia, the relationship between plasma Abeta40 and Abeta42 levels and ApoE phenotypes in children with DS has not been examined. Inflammation might play a role in the growth of DS brains. Neopterin is an immune activation marker for the cell-mediated immune response.
OBJECTIVE: To examine the levels of plasma Abeta40, Abeta42, and neopterin in children or adolescents with DS or controls.
MATERIALS AND METHODS: Blood was collected from DS (N=35; 7+/-3.8 years old) and their siblings (N=34; 10+/-4.5). Plasma Abeta40 and Abeta42, and neopterin levels were quantitated by sandwich ELISA.
RESULTS: Abeta40 and Abeta42 levels were higher in DS than controls. The ratio of Abeta42/Abeta40 was lower in DS than in controls. There were significant negative correlations between age and Abeta40 in DS and controls, and between age and Abeta42 levels in DS but not in controls. There was no association of Abeta40 or Abeta42 levels with Apo E in either group. Neopterin levels were higher in DS than controls, and the levels were not correlated with Abeta40 and Abeta42 levels in DS or controls.
CONCLUSIONS: The over expression of APP gene in DS leads to increases in plasma Abeta40 and Abeta42 levels before plaque formation in DS brain. Higher neopterin concentrations in DS reflect inflammatory cell activation. Further studies are needed to determine whether DS children with lower plasma Abeta42/Abeta40 ratios are at increased risk of developing AD during aging than those with higher ratios.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17275850     DOI: 10.1016/j.jns.2006.12.010

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  27 in total

1.  Gene expression variation increase in trisomy 21 tissues.

Authors:  Ching Yu Chou; Li Yu Liu; Chien Yu Chen; Cheng Hsien Tsai; Hsiao Lin Hwa; Li Yun Chang; Yi Shing Lin; Fon Jou Hsieh
Journal:  Mamm Genome       Date:  2008-07-02       Impact factor: 2.957

Review 2.  The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer's Disease.

Authors:  Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2015-01-07       Impact factor: 5.590

Review 3.  Synthetic combinations of missense polymorphic genetic changes underlying Down syndrome susceptibility.

Authors:  Rebecca A Jackson; Mai Linh Nguyen; Angela N Barrett; Yuan Yee Tan; Mahesh A Choolani; Ee Sin Chen
Journal:  Cell Mol Life Sci       Date:  2016-05-31       Impact factor: 9.261

Review 4.  Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics.

Authors:  Marzia Perluigi; Fabio Di Domenico; D Allan Buttterfield
Journal:  Proteomics Clin Appl       Date:  2014-02       Impact factor: 3.494

5.  Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome.

Authors:  Elizabeth Head; Eric Doran; Mihaela Nistor; MaryAnn Hill; Frederick A Schmitt; Richard J Haier; Ira T Lott
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 6.  HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.

Authors:  Eugenio Barone; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2016-11-10       Impact factor: 7.376

7.  Amyloid-associated depression: a prodromal depression of Alzheimer disease?

Authors:  Xiaoyan Sun; David C Steffens; Rhoda Au; Marshal Folstein; Paul Summergrad; Jacqueline Yee; Irwin Rosenberg; D Mkaya Mwamburi; Wei Qiao Qiu
Journal:  Arch Gen Psychiatry       Date:  2008-05

8.  Effect of Anticoagulants on Amyloid β-Protein Precursor and Amyloid Beta Levels in Plasma.

Authors:  Cara J Westmark; Crystal M Hervey; Elizabeth M Berry-Kravis; James S Malter
Journal:  J Alzheimers Dis Parkinsonism       Date:  2011-07-24

9.  Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome.

Authors:  V P Prasher; S G Sajith; P Mehta; W B Zigman; N Schupf
Journal:  Int J Geriatr Psychiatry       Date:  2010-02       Impact factor: 3.485

Review 10.  Biomarkers for cognitive impairment and dementia in elderly people.

Authors:  Joshua A Sonnen; Kathleen S Montine; Joseph F Quinn; Jeffrey A Kaye; John C S Breitner; Thomas J Montine
Journal:  Lancet Neurol       Date:  2008-08       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.